By CapitalSnitch Research Desk · updated Oct 11, 2026 · data from SEC filings and official Congress disclosures
Over the last 12 months, three Aldeyra Therapeutics, Inc. the people running the company bought shares on the open market, about $523,000 in total, and none of them sold.
Biggest single buyer: Brady Todd C, CEO, with roughly $418,000. That includes C-suite money, which tends to get the most attention.
On the institutional side, 108 funds reported holding ALDX at the end of Q2 2026, and more funds sold than bought. Looking at the quarterly pattern: No open-market insider buying or selling in the last full quarter. Insiders bought in 3 of the last 7 full quarters.
Are insiders buying or selling ALDX stock?
In the last 12 months Aldeyra Therapeutics, Inc. insiders made open-market purchases worth about $523,000 and sales worth about $0. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
When was the last insider trade in ALDX?
The most recent open-market insider trade in ALDX was filed on 2026-06-05.
How many institutions own ALDX?
108 investment managers reported holding ALDX in SEC Form 13F filings for Q2 2026.
Has any member of Congress traded ALDX?
No congressional trades in ALDX were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1).
Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).